Associated tags: NSCLC, MAIA, Patient, Cancer, Biotechnology, Health, Oncology, Pharmaceutical, Clinical Trials, NYSE, Pharmaceutical industry, Research, Science, Safety
Locations: SPAIN, NEW YORK, AUSTRALIA/OCEANIA, PARK AVENUE, RARE, OHIO, IR, SIMON, IL, ROMANIA, GILEAD, UNITED STATES, NORTH AMERICA, ILLINOIS, CRISTIAN, CHICAGO, GERMANY, TURKEY, ADELINA
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA’s common stock as part of the Company’s recent private placement of common stock and warrants to accredited investors and certain Company directors.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 19,665 shares, and warrants for 19,665 shares, of MAIA’s common stock as part of the Company’s recent private placement of common stock and warrants to accredited investors and certain Company directors.
- The securities sold to the Company directors participating in the offering were issued pursuant to the Company’s 2021 Equity Incentive Plan.
- Ms. Louie has 30 years of service with HSBC Group in a variety of functions, principally with businesses of Global Banking and Markets including investment and securities management, asset management, and global research.
- Most recently she was the Chief Operating Officer of Internal Audit at HSBC Group.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Sale,
University,
Cancer,
Textbook,
Economics,
Security (finance) MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock as part of the Company’s recent private placement of common stock and warrants.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 147,492 shares, and warrants for 147,492 shares, of MAIA’s common stock as part of the Company’s recent private placement of common stock and warrants.
- On April 23, 2024, MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors.
- Each share of common stock was offered together with a warrant to purchase one share of common stock at an exercise price of $2.26 per share.
- The gross proceeds from the offering are approximately $1.0 million, prior to offering expenses payable by the Company.
Biotechnology,
Pharmaceutical,
Health,
Oncology,
Sale,
Cancer,
Regulation D,
Research,
Exercise,
NSCLC,
Lung cancer,
Security (finance) MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited investors and certain Company directors.
- The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date.
- The private placement is expected to close on or about April 25, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the offering are expected to be approximately $1.00 million, prior to offering expenses payable by the Company.
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
Clinical Trials,
Lung cancer,
Trial of the century,
MAIA,
FDA,
DNA,
Clinical trial,
News,
NSCLC,
Pharmaceutical industry Participants should refer to the final program agendas for up-to-date information.
Key Points:
- Participants should refer to the final program agendas for up-to-date information.
- MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses.
- Recent news from MAIA’s THIO-101 trial includes:
Early completion of enrollment; topline data expected in second half of 2024; ( press release, February 22, 2024 )
Strong response rate of 38% in third-line treatment efficacy data; ( press release, March 6, 2024 ).
- Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; ( MAIA Shareholder Letter 2024 ).
MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M.
- made individual purchases of 69,282 and 6,928 shares of common stock, respectively, as part of the Company’s recent private placement of common stock and warrants.
- “I believe MAIA is well positioned to create a great deal of value for its shareholders over time,” added Mr. Guerrero.
- Over the course of his career, Mr. Luput has successfully completed multiple multi-million dollar real estate partnerships, consolidations, mergers, and acquisitions.
Oncology,
Health,
Other Science,
Clinical Trials,
Science,
Pharmaceutical,
Biotechnology,
Yee,
Internal audit,
Market,
Cancer,
HSBC MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
- Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, “Our ongoing progress has encouraged our top investors to continue participating in our offerings.
- We appreciate the support of our top investor, Adelina, alongside Stan Smith’s participation in the same offering .
- Most recently she was the Chief Operating Officer of Internal Audit at HSBC Group.
Oncology,
Health,
Other Health,
Other Science,
Clinical Trials,
Science,
Biotechnology,
Lung cancer,
Cancer,
Research,
Sale,
Exercise,
NSCLC,
Regulation D,
Security (finance) MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per share, in a private placement to accredited investors.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per share, in a private placement to accredited investors.
- The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date.
- The private placement is expected to close on or about March 28, 2024, subject to the satisfaction of customary closing conditions.
- The gross proceeds from the offering are expected to be approximately $1.33 million, prior to offering expenses payable by the Company.
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
General Health,
Other Science,
Science,
Oncology,
University,
MAIA,
Sale,
Textbook,
Cancer,
Economics MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Mr. Stan V. Smith, Ph.D. made an individual purchase of 170,940 shares of the Company’s common stock as part of the Company’s recent private placement of common stock and warrants.
- On March 11, 2024, MAIA entered into a Securities Purchase Agreement with certain accredited investors for the issuance and sale in a private placement of 2,043,587 shares of the Company’s common stock, and warrants to purchase up to 2,043,587 shares of the Company’s common stock, at a price per share of $1.17.
- The combined gross proceeds from the private placement, closed on March 14, 2024, were approximately $2.9 million, prior to deducting offering expenses payable by the Company.
- Trained at the University of Chicago and specializing in litigation economics, Dr. Smith co-authored the first textbook on the subject of economic damages.
Research,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Oncology,
Lung cancer,
Internal medicine,
Immunotherapy,
Patient,
Cancer,
Human,
Quality of life,
Hacettepe University,
Breast cancer,
Melanoma,
SAB,
Poster,
Multimedia,
University of Regensburg MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D.
Key Points:
- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D.
- View the full release here: https://www.businesswire.com/news/home/20240321173734/en/
Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire)
Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hospital in Turkey.
- “He is a prominent voice on medical oncology and cancer epidemiology, with a special interest in quality of life for cancer patients.
- In the same year, he graduated from the Cancer Epidemiology Master's Program at the Hacettepe University Oncology Institute, Department of Preventive Oncology.
Retrieved on:
Tuesday, February 27, 2024
Biotechnology,
MAIA,
Gilead Sciences,
Medicine,
ASH,
ASCO,
SAB,
FDA,
Drug development,
AbbVie,
European Hematology Association,
Mantle cell lymphoma,
Pleasure,
Kite Pharma,
Hematology,
EHA,
University,
Society,
University of Bern,
Patient,
NK,
Pharmacyclics,
Acute lymphoblastic leukemia,
Publication,
Research,
Cancer,
Pharmaceutical industry CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
Key Points:
- CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB).
- Dr. Vezan currently serves as Vice President, Global Clinical Development at BeiGene.
- Vezan holds vast experience in guiding oncology assets through all stages of development, from research to clinical strategies and registration.
- Dr. Remus Vezan commented, “It is my pleasure and privilege to join MAIA as scientific advisor and support the efforts of the MAIA team in advancing the clinical development of its first-in-class telomere targeting agent.
